

Giant Biogene (2367 HK)

Strong Performance in 2024

Giant Biogene announced strong 2024 results, with revenue up by 57% YoY to RMB5.5bn. Revenue from skincare products and medical dressing increased by 62.5% YoY and 41.5% YoY, respectively. The increase in revenue proportion of skincare products led to a decline in GPM from 83.6% in 2023 to 82.1% in 2024. Online revenue increased by 70.0% YoY, with revenue contribution rising to 71.6%. Due to the increased proportion of online revenue and rising marketing costs on Tmall and Douyin, the Company's selling expense ratio increased by 3.2 ppts to 36.3% in 2024. Therefore, attributable NPM decreased by 4 ppts to 37.2%.

- **Comfy maintains robust growth with successful category expansion.** In 2024, Comfy's revenue increased by 62.9% YoY to RMB4.5bn. We estimate that revenue proportion of collagen sticks and dressings decreased to below 30% each, with other products continuously achieving solid growth. We estimated *Comfy Focus Cream* generated revenue of over RMB200mn in 2024, and we expect it to potentially double this year. According to Moojing, in 2M25, Comfy maintained strong growth momentum, with total GMV on Tmall, JD.com, and Douyin increasing by 60% YoY. Notably, the lotion/cream category's GMV on Tmall increased by over 240% YoY in 2M25. We think the successful launch of *Focus Cream* further validates Comfy's ability to create blockbuster products. With the continuous expansion of product categories, we expect Comfy to grow rapidly.
- **Collgene accelerated growth.** In 2024, Collgene's revenue increased by 36.3% YoY to RMB840mn, with 2H24 revenue increasing by 50.1% YoY. We think the growth acceleration was driven by 1) robust online sales growth (according to Moojing, Collgene's total GMV on Tmall, JD.com, and Douyin increased by 103% YoY in 2024); and 2) headwinds from the revenue decline of Xi'an Chuangkecun business waning). We estimate that Collgene's offline revenue only accounted for approximately 30% in 2024, and online sales gradually unleashed growth potential. According to Moojing, Collgene's total GMV on Tmall, JD.com, and Douyin increased by over 180% YoY in 2M25, a significant acceleration compared to 2M24.
- **Approval of injectable products delayed.** The product targeting moderate to severe neck wrinkles (Injectable Recombinant Collagen Filler) was granted priority approval in Dec 2024 but the product targeting forehead lines and crow's feet, which was expected to be approved in 1Q25, remains pending. However, the Company has begun to prepare for commercialization and expand its medical aesthetics team. Leveraging its wide distribution network and brand strength in medical aesthetics from medical dressings and the newly launched "Intensive Repair" portfolios, we believe Giant Biogene is still well-positioned for long-term growth in medical aesthetics market despite approval delays.
- **Maintain BUY.** We believe the successful expansion of product portfolios will drive Giant Biogene's long-term rapid growth. Additionally, four injectable products are currently in the application phase and nearing commercialization. We raise our TP of HK\$79.96 based on a 9-year DCF model (WACC: 10.9%, terminal growth rate: 3.0%) considering the strong performance in 2024 and long-term growth potential.

Earnings Summary

(YE 31 Dec)	FY23A	FY24A	FY25E	FY26E	FY27E
Revenue (RMB mn)	3,524	5,539	7,138	9,320	11,944
YoY growth (%)	49.0	57.2	28.9	30.6	28.2
Adjusted net profit (RMB mn)	1,452	2,152	2,473	3,056	3,748
YoY growth (%)	37.4	48.2	15.0	23.6	22.6
P/E (x)	42.4	30.0	26.1	21.2	17.3
Net gearing (%)	(57.2)	(56.5)	(63.4)	(69.0)	(73.6)

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price	HK\$79.96
(Previous TP)	HK\$69.19)
Up/Downside	18.5%
Current Price	HK\$67.45

China Healthcare

Jill WU, CFA
(852) 3900 0842
jillwu@cmbi.com.hk

Cathy WANG
(852) 3916 1729
cathywang@cmbi.com.hk

Miao ZHANG
(852) 3761 8910
zhangmiao@cmbi.com.hk

Bella LI
(852) 3757 6202
bellali@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	69,871.7
Avg 3 mths t/o (HK\$ mn)	199.8
52w High/Low (HK\$)	72.80/35.70
Total Issued Shares (mn)	1035.9

Source: FactSet

Shareholding Structure

Juzi Holding Co., Ltd	56.5%
-----------------------	-------


Source: HKEx

Share Performance

	Absolute	Relative
1-mth	5.8%	6.4%
3-mth	34.2%	14.4%
6-mth	39.6%	22.2%

Source: FactSet

12-mth Price Performance



Source: FactSet

Figure 1: Earnings revision

RMB mn	New			Old			Diff (%)		
	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	7,138	9,320	11,944	7,288	9,729	12,481	-2.1%	-4.2%	-4.3%
Gross profit	5,784	7,486	9,571	5,905	7,813	9,998	-2.0%	-4.2%	-4.3%
Net profit	2,502	3,085	3,777	2,594	3,300	4,046	-3.6%	-6.5%	-6.6%
EPS (RMB)	2.42	2.98	3.65	2.52	3.21	3.93	-4.3%	-7.2%	-7.3%
Gross margin	81.03%	80.32%	80.13%	81.02%	80.31%	80.10%	+0.01 ppt	+0.02 ppt	+0.03 ppt
Net margin	35.05%	33.10%	31.62%	35.60%	33.92%	32.42%	-0.54 ppt	-0.82 ppt	-0.80 ppt

Source: Company data, CMBIGM estimates

Figure 2: Risk-adjusted DCF valuation

DCF Valuation (in RMB mn)	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E
EBIT	2,809	3,445	4,197	5,069	5,981	6,998	8,118	9,336	10,643
Tax rate	15.0%	15.0%	15.0%	15.0%	15.0%	15.0%	15.0%	15.0%	15.0%
EBIT*(1-tax rate)	2,388	2,929	3,568	4,309	5,084	5,948	6,900	7,935	9,046
+ D&A	62	67	71	75	89	104	120	139	158
- Change in working capital	-45	-95	-109	-139	-164	-192	-222	-256	-292
- Capex	-180	-150	-150	-150	-177	-207	-240	-276	-315
FCFF	2,225	2,751	3,380	4,095	4,832	5,654	6,558	7,542	8,598
Terminal value									111,461

Terminal growth rate	3.0%
WACC	10.9%
Cost of Equity	14.6%
Cost of Debt	5.0%
Equity Beta	1.10
Risk Free Rate	3.0%
Market Risk Premium	10.5%
Target Debt to Asset ratio	35.0%
Effective Corporate Tax Rate	15.0%

Terminal value (RMB mn)	43,768
Total PV (RMB mn)	68,923
Net debt (RMB mn)	-5,633
Minority interest (RMB mn)	11
Equity value (RMB mn)	74,545
Equity value (HK\$ mn)	82,828
# of shares (mn)	1,036
Price per share (HK\$ per share)	79.96

Source: CMBIGM estimates

Figure 3: Sensitivity analysis

		WACC				
		9.9%	10.4%	10.9%	11.4%	11.9%
Terminal growth rate	4.0%	103.10	94.54	87.24	80.94	75.46
	3.5%	97.46	89.89	83.35	77.67	72.68
	3.0%	92.64	85.86	79.96	74.78	70.20
	2.5%	88.46	82.34	76.96	72.21	67.99
	2.0%	84.81	79.23	74.30	69.92	66.00

Source: CMBIGM estimates

Figure 4: CMBIGM estimates vs consensus

RMB mn	CMBIGM			Consensus			Diff (%)		
	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	7,138	9,320	11,944	6,849	8,605	10,706	4.2%	8.3%	11.6%
Gross profit	5,784	7,486	9,571	5,627	7,050	8,732	2.8%	6.2%	9.6%
Net profit	2,502	3,085	3,777	2,530	3,125	3,282	-1.1%	-1.3%	15.1%
EPS (RMB)	2.42	2.98	3.65	2.49	2.50	3.08	-2.9%	19.0%	18.3%
Gross margin	81.03%	80.32%	80.13%	82.15%	81.93%	81.56%	-1.12 ppt	-1.61 ppt	-1.43 ppt
Net margin	35.05%	33.10%	31.62%	36.94%	36.32%	30.66%	-1.89 ppt	-3.21 ppt	+0.97 ppt

Source: Company data, Bloomberg, CMBIGM estimates

Figure 5: Peer comparison

Company	Ticker	Rating	Price (LC)	Mkt cap (\$mn)	PE		PB		PS		ROE (%)	
					FY25E	FY26E	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E
H share												
GIANT BIOGENE HOLDING CO LTD	2367 HK	BUY	67.5	8,985	26.1	21.2	7.3	5.9	8.7	6.6	31.3	30.9
A share												
IMEIK TECHNOLOGY DEVELOPMENT-A (爱美客)	300896 CH	NA	184.1	7,669	24.9	21.5	6.0	5.1	16.0	13.8	24.9	24.4
PROYA *COSMETICS CO LTD-A (珀莱雅)	603605 CH	BUY	84.1	4,585	17.8	15.0	4.9	3.9	2.4	2.1	28.7	27.4
BLOOMAGE BIOTECHNOLOGY COR-A (华熙生物)	688363 CH	NA	50.5	3,345	38.2	30.7	3.2	3.0	3.8	3.3	8.2	9.3
SHANXI JINBO BIO-PHARMACEUTICALS-A (锦波生物)	832982 CH	NA	299.0	3,643	25.8	20.2	10.6	6.9	13.5	10.5	41.2	36.0
HARBIN FUERJIA TECHNOLOGY -A (敷尔佳)	301371 CH	NA	35.1	1,935	17.5	15.8	2.0	1.8	5.9	5.4	11.2	11.3
Average					24.8	20.6	5.3	4.1	8.3	7.0	22.8	21.7

Source: Bloomberg, CMBIGM estimates, as of 27 Mar, 2025. *Note: Covered by CMBI consumer staples team

Financial Summary

INCOME STATEMENT	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (RMB mn)						
Revenue	2,364	3,524	5,539	7,138	9,320	11,944
Cost of goods sold	(369)	(577)	(992)	(1,354)	(1,834)	(2,373)
Gross profit	1,995	2,947	4,547	5,784	7,486	9,571
Selling expense	(706)	(1,164)	(2,008)	(2,731)	(3,705)	(4,928)
Admin expense	(111)	(97)	(151)	(178)	(233)	(299)
R&D expense	(44)	(75)	(106)	(121)	(158)	(203)
Other income	69	103	139	161	211	273
Other expense	(1)	(0)	(3)	(15)	(15)	(15)
Other gains/(losses)	(23)	31	44	44	44	44
Interest expense	(0)	(0)	(0)	(0)	(0)	(0)
Others	(1)	1	(0)	0	0	0
Pre-tax profit	1,178	1,745	2,458	2,943	3,629	4,443
Income tax	(176)	(297)	(396)	(441)	(544)	(666)
After tax profit	1,002	1,448	2,062	2,501	3,085	3,776
Minority interest	(0)	(4)	(1)	(1)	(1)	(1)
Attributable net profit	1,002	1,452	2,062	2,502	3,085	3,777
Adjusted net profit	1,056	1,452	2,152	2,473	3,056	3,748

BALANCE SHEET	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (RMB mn)						
Current assets	2,538	4,135	6,402	8,073	10,282	12,995
Cash & equivalents	1,331	2,504	4,030	5,640	7,643	10,119
Account receivables	69	102	141	157	205	262
Inventories	184	200	311	349	473	612
Financial assets at FVTPL	866	1,275	1,829	1,829	1,829	1,829
Other current assets	87	54	91	99	134	173
Non-current assets	600	838	1,636	1,754	1,836	1,914
PP&E	491	663	1,042	1,164	1,251	1,333
Right-of-use assets	60	48	51	46	41	36
Deferred income tax	1	1	1	1	1	1
Intangibles	7	7	6	6	7	8
Other non-current assets	41	118	536	536	536	536
Total assets	3,138	4,973	8,038	9,826	12,118	14,909
Current liabilities	281	531	836	853	965	1,091
Account payables	55	133	287	287	388	502
Tax payable	75	117	117	117	117	117
Other current liabilities	138	243	410	410	410	410
Lease liabilities	1	2	5	5	5	5
Contract liabilities	12	36	17	34	44	57
Non-current liabilities	20	71	82	82	82	82
Deferred income	18	20	19	19	19	19
Other non-current liabilities	2	52	63	63	63	63
Total liabilities	301	602	918	935	1,047	1,174
Ordinary share capital	0	0	0	0	0	0
Preferred share capital	0	0	0	0	0	0
Treasury shares	(0)	(0)	(0)	(0)	(0)	(0)
Other reserves	2,833	4,362	7,108	8,880	11,061	13,726
Minority interest	4	9	12	11	10	10
Total equity	2,837	4,371	7,120	8,891	11,071	13,735
Total equity and liabilities	3,138	4,973	8,038	9,826	12,118	14,909

CASH FLOW	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	1,178	1,745	2,458	2,943	3,629	4,443
Depreciation & amortization	28	34	49	62	67	71
Tax paid	(173)	(206)	(396)	(441)	(544)	(666)
Change in working capital	(132)	128	115	(45)	(95)	(109)
Others	31	(54)	(127)	(110)	(160)	(222)
Net cash from operations	932	1,647	2,098	2,409	2,897	3,517
Investing						
Capital expenditure	(153)	(226)	(200)	(180)	(150)	(150)
Others	(706)	(301)	109	131	181	243
Net cash from investing	(859)	(527)	(91)	(49)	31	93
Financing						
Dividend paid	0	0	0	0	0	0
Proceeds from share issues	508	0	0	0	0	0
Others	(6,298)	52	390	(751)	(926)	(1,133)
Net cash from financing	(5,790)	52	390	(751)	(926)	(1,133)
Net change in cash						
Cash at the beginning of the year	7,103	1,331	2,504	4,030	5,640	7,643
Exchange difference	(55)	1	0	0	0	0
Cash at the end of the year	1,331	2,504	4,902	5,640	7,643	10,119
GROWTH	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec						
Revenue	52.3%	49.0%	57.2%	28.9%	30.6%	28.2%
Gross profit	47.3%	47.7%	54.3%	27.2%	29.4%	27.8%
Net profit	21.0%	44.9%	42.1%	21.3%	23.3%	22.4%
Adj. net profit	24.1%	37.4%	48.2%	15.0%	23.6%	22.6%
PROFITABILITY	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec						
Gross profit margin	84.4%	83.6%	82.1%	81.0%	80.3%	80.1%
Adj. net profit margin	44.7%	41.2%	38.8%	34.6%	32.8%	31.4%
Return on equity (ROE)	52.0%	40.3%	35.9%	31.3%	30.9%	30.5%
GEARING/LIQUIDITY/ACTIVITIES	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec						
Net debt to equity (x)	(0.5)	(0.6)	(0.6)	(0.6)	(0.7)	(0.7)
Current ratio (x)	9.0	7.8	7.7	9.5	10.7	11.9
VALUATION	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec						
P/E	63.6	42.4	30.0	26.1	21.2	17.3
P/E (diluted)	64.2	42.6	30.6	26.1	21.2	17.3
P/B	15.6	14.1	8.7	7.3	5.9	4.8
Div yield (%)	0.0	1.4	2.0	1.2	1.4	1.7

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.